Dr. Reddy's Laboratories Limited (RDY) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Hyderabad, India. The current CEO is Erez Israeli.
RDY has IPO date of 2001-04-11, 27,048 full-time employees, listed on the NYSE, a market capitalization of $10.93B.
Dr. Reddy's Laboratories Limited is an integrated pharmaceutical company headquartered in Hyderabad, India, operating globally across multiple therapeutic areas including gastroenterology, cardiology, diabetes, dermatology, oncology, and respiratory medicine. The company operates through four primary segments: Global Generics, which manufactures prescription and over-the-counter finished pharmaceuticals and biologics; Pharmaceutical Services and Active Ingredients, which produces active pharmaceutical ingredients, intermediates, and contract research services; Proprietary Products, focused on differentiated formulation development; and Others, dedicated to oncology and inflammation therapies. With a strong presence in generic and branded pharmaceuticals worldwide, Dr. Reddy's has established strategic partnerships, including a collaboration with Curis, Inc. for immuno-oncology and precision oncology development. Founded in 1984, the company continues to expand its portfolio across developed and emerging markets.
